SERES

SERES

Develops microbiome-based therapies for diseases

About SERES

Simplify's Rating
Why SERES is rated
A
Rated B on Competitive Edge
Rated A on Growth Potential
Rated A+ on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

201-500

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Overview

Seres Therapeutics develops microbiome-based therapies that use beneficial bacteria to treat diseases, particularly focusing on conditions like Clostridium difficile infection (CDI) and other gastrointestinal disorders. Their approach aims to restore the natural balance of bacteria in the human body, addressing the root causes of these diseases. The company operates from Cambridge, Massachusetts, where it conducts research, clinical trials, and manufacturing. Unlike many competitors, Seres Therapeutics emphasizes a strong commitment to research and development, which allows them to create targeted treatments for unmet medical needs. Their goal is to improve patient outcomes through effective microbiome therapies, generating revenue from the sale of approved treatments and potential licensing agreements.

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's positive feedback on SER-155 supports a favorable regulatory environment.
  • Seres received a $50 million installment from Nestlé, boosting financial resources.
  • Completion of SER-155 Phase 1B trial enrollment indicates progress in clinical milestones.

What critics are saying

  • Over-reliance on Nestlé Health Science for financial stability is a concern.
  • Loss of key personnel like Caroline Hensley may impact legal and compliance functions.
  • Intensifying competition in microbiome therapeutics could challenge Seres' market position.

What makes SERES unique

  • Seres Therapeutics specializes in microbiome-based therapies, a revolutionary treatment approach.
  • The company has a strong executive team with extensive experience in drug development.
  • Seres operates from Cambridge, Massachusetts, with integrated research and manufacturing facilities.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$254.5M

Above

Industry Average

Funded Over

5 Rounds

Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Debt Funding Comparison
Coming Soon

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

-2%

2 year growth

14%
AutoIni
Mar 11th, 2025
DFSK Gelora E Blind Van - Most Popular at IIMS 2025

Both DFSK and Seres were also awarded coveted honors for their electrification campaigns at IIMS 2025.

Investing.com
Mar 3rd, 2025
FDA supports Seres Therapeutics' study endpoint

CAMBRIDGE, Mass. - Seres Therapeutics, Inc. (NASDAQ:MCRB), a biotechnology firm specializing in live biotherapeutics with a market capitalization of $130 million, has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its clinical development strategy for SER-155, an investigational treatment for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

TipRanks
Feb 27th, 2025
Seres Therapeutics Announces CMO Resignation in March 2025

Lisa von Moltke will resign from Seres Therapeutics in March 2025.

Benzinga
Jan 16th, 2025
Seres Therapeutics Announces Receipt Of Expected $50 Million Installment Payment Related To Vowst Sale

CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. MCRB (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Company's previously announced sale of its VOWST business to Société des Produits Nestlé S.A (SPN, and with certain of its affiliates, collectively, Nestlé Health Science). This installment payment was expected as Seres is fulfilling its transition obligations. As previously announced, based on the Company's existing cash, inclusive of this payment, a projected installment payment from Nestlé Health Science in July 2025 of $25 million (less up to approximately $1.5M in employment-related payments to Nestlé Health Science), transaction-related obligations and current operating plans, the Company expects to fund operations into the first quarter of 2026. About Seres Therapeutics  Seres Therapeutics, Inc. MCRB is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics

Stock Titan
Dec 16th, 2024
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

Hensley joins from Seres Therapeutics, where she served as senior vice president, assistant general counsel and chief compliance officer, overseeing corporate legal and compliance matters.

Recently Posted Jobs

Sign up to get curated job recommendations

Sr – Motor Control Engineer

Milpitas, CA, USA

SERES is Hiring for 1 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update SERES's jobs every few hours, so check again soon! Browse all jobs →

SERES is Hiring for 1 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update SERES's jobs every few hours, so check again soon! Browse all jobs →

People Also Viewed

Discover companies similar to SERES

Vedanta Biosciences

Vedanta Biosciences

Cambridge, Massachusetts

Serán BioScience

Serán BioScience

Bend, Oregon

Sana Biotechnology

Sana Biotechnology

Seattle, Washington